Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $8.82, for a total value of $100,962.54. Following the completion of the transaction, the director now owns 7,241,308 shares of the company’s stock, valued at approximately $63,868,336.56. The sale was disclosed in a document filed with the SEC, which is available at this link.

Blake Borgeson also recently made the following trade(s):

  • On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.79, for a total value of $216,382.66.
  • On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total value of $241,851.24.
  • On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $247,065.28.
  • On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.30, for a total value of $106,457.10.
  • On Tuesday, January 23rd, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.58, for a total value of $212,171.32.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX opened at $8.93 on Thursday. The firm has a 50 day simple moving average of $11.08 and a 200-day simple moving average of $9.07. Recursion Pharmaceuticals, Inc. has a one year low of $4.54 and a one year high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The company had revenue of $10.89 million for the quarter, compared to analyst estimates of $12.37 million. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after buying an additional 13,777,689 shares in the last quarter. Mubadala Investment Co PJSC bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at $128,041,000. Nvidia Corp bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $75,985,000. FMR LLC lifted its stake in shares of Recursion Pharmaceuticals by 134.4% during the third quarter. FMR LLC now owns 10,689,532 shares of the company’s stock valued at $81,775,000 after acquiring an additional 6,129,935 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Recursion Pharmaceuticals by 161.2% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after acquiring an additional 5,680,656 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on RXRX. KeyCorp upped their price target on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th. Needham & Company LLC upped their price target on shares of Recursion Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. Finally, TD Cowen started coverage on shares of Recursion Pharmaceuticals in a report on Friday, January 26th. They set a “market perform” rating on the stock. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $12.75.

Get Our Latest Research Report on RXRX

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Featured Articles

Insider Buying and Selling by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.